Macdonald Kai, Feifel David
University of California, San Diego Medical Center Department of Psychiatry.
Acta Neuropsychiatr. 2012 Jun;24(3):130-46. doi: 10.1111/j.1601-5215.2011.00634.x. Epub 2011 Dec 19.
The suggestion that the neurohormone oxytocin may have clinical application in the treatment of schizophrenia was first published in 1972. Since then, a considerable body of research on a variety of fronts--including several recent double-blind treatment trials-has buttressed these early reports, providing support for the assertion that the oxytocin system is a promising and novel therapeutic target for this devastating malady. Herein, we review the diverse, convergent lines of evidence supporting the therapeutic potential of oxytocin in psychotic illness.
We performed a systematic review of preclinical and clinical literature pertaining to oxytocin's role in schizophrenia.
Multiple lines of evidence converge to support the antipsychotic potential of oxytocin. These include several animal models of schizophrenia, pharmacological studies examining the impact of antipsychotics on the oxytocin system, human trials in patients examining aspects of the oxytocin system, and several double-blind, placebo-controlled clinical treatment trials.
There exists considerable, convergent evidence that oxytocin has potential as a novel antipsychotic with a unique mechanism of action. Auspiciously, based on the few chronic trials to date, its safety profile and tolerability appear very good. That said, several critical clinical questions await investigation before widespread use is clinically warranted.
神经激素催产素可能在精神分裂症治疗中具有临床应用价值这一观点于1972年首次发表。从那时起，在多个方面进行的大量研究——包括最近的几项双盲治疗试验——支持了这些早期报道，为催产素系统是这种严重疾病一个有前景的新型治疗靶点这一论断提供了依据。在此，我们综述支持催产素在精神病性疾病中治疗潜力的各种相互印证的证据。
我们对与催产素在精神分裂症中作用相关的临床前和临床文献进行了系统综述。
多条证据相互印证，支持催产素的抗精神病潜力。这些证据包括几种精神分裂症动物模型、研究抗精神病药物对催产素系统影响的药理学研究、针对患者催产素系统方面的人体试验，以及几项双盲、安慰剂对照的临床治疗试验。
有大量相互印证的证据表明，催产素作为一种具有独特作用机制的新型抗精神病药物具有潜力。幸运的是，基于迄今为止为数不多的长期试验，其安全性和耐受性似乎非常良好。话虽如此，在临床上有必要广泛使用之前，仍有几个关键的临床问题有待研究。
